Literature DB >> 30126780

Tumor suppressor protein p53 negatively regulates ischemia-induced angiogenesis and arteriogenesis.

Miles J Pfaff1, Subhradip Mukhopadhyay2, Mark Hoofnagle2, Christine Chabasse2, Rajabrata Sarkar2.   

Abstract

OBJECTIVE: The tumor suppressor protein p53 regulates angiogenesis and is a key regulatory mediator of cellular apoptosis, proliferation, and growth. p53 expression is induced in response to ischemia; however, its role in regulating ischemia-induced angiogenesis and arteriogenesis remains undefined. The objective of this study was to define the role of p53 in regulating ischemia-induced angiogenesis and arteriogenesis and to identify mechanisms by which this regulation occurs in vivo.
METHODS: Surgically induced hindlimb ischemia or mesenteric artery ligation was performed in wild-type (p53+/+) and p53 knockout (p53-/-) mice. Limb perfusion and revascularization were assessed by laser Doppler perfusion imaging, capillary density, and collateral artery development. Mesenteric collateral artery flow and development were determined by arterial flow measurement and by histologic analysis, respectively. An in vitro aortic ring assay was performed on p53+/+ and p53-/- aortic tissue to evaluate endothelial function. The p53 inhibitor and activator pifithrin-α and quinacrine, respectively, were used to modulate p53 activity in vivo after ischemia.
RESULTS: Absence of p53 in mice resulted in increased limb perfusion (P < .05), capillary density (P < .05), and collateral artery development (P < .05) after induction of hindlimb ischemia. In the nonischemic mesenteric artery ligation model of arteriogenesis, p53 expression was induced in collateral arteries and increased arterial blood flow in mice lacking p53 (P < .05). Lack of p53 decreased apoptosis in ischemic hindlimb tissue (P < .05) and increased proangiogenic factors hypoxia-inducible factor 1α and vascular endothelial growth factor (VEGF). Endothelial cell outgrowth in vitro increased in the absence of p53 (P < .05). Pharmacologic augmentation of p53 expression after ischemia impaired perfusion and collateral artery formation and decreased VEGF levels (P < .05). Conversely, inhibition of p53 with pifithrin-α augmented limb perfusion (P < .05) and collateral artery formation (P < .05) and increased protein levels of hypoxia-inducible factor 1α and VEGF. Pharmacologic augmentation and inhibition of p53 had no significant effect in mice lacking p53.
CONCLUSIONS: p53 negatively regulates ischemia-induced angiogenesis and arteriogenesis. Inhibition of p53 increases ischemia-induced arteriogenesis and limb perfusion and thus represents a potential therapeutic strategy for arterial occlusive disease.
Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Arteriogenesis; HIF-1α; Hypoxia-inducible factor 1α; Ischemia; Neovascularization; VEGF; Vascular endothelial growth factor; p53

Mesh:

Substances:

Year:  2018        PMID: 30126780     DOI: 10.1016/j.jvs.2018.02.055

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  8 in total

1.  PAQR3 Inhibits Non-small Cell Lung Cancer Growth by Regulating the NF-κB/p53/Bax Axis.

Authors:  Qiang Guo; Xi-Xian Ke; Shi-Xu Fang; Wei-Long Gao; Yong-Xiang Song; Cheng Chen; Hong-Ling Lu; Gang Xu
Journal:  Front Cell Dev Biol       Date:  2020-10-06

2.  Deficiency of lncRNA SNHG12 impairs ischemic limb neovascularization by altering an endothelial cell cycle pathway.

Authors:  David A Gross; Henry S Cheng; Rulin Zhuang; Michael G McCoy; Daniel Pérez-Cremades; Zachary Salyers; A K M Khyrul Wara; Stefan Haemmig; Terence E Ryan; Mark W Feinberg
Journal:  JCI Insight       Date:  2022-01-11

3.  Novel and Annotated Long Noncoding RNAs Associated with Ischemia in the Human Heart.

Authors:  Zoe Ward; Sebastian Schmeier; Louis Saddic; Martin I Sigurdsson; Vicky A Cameron; John Pearson; Allison Miller; Arthur Morley-Bunker; Josh Gorham; Jonathan G Seidman; Christine S Moravec; Wendy E Sweet; Sary F Aranki; Simon Body; Jochen D Muehlschlegel; Anna P Pilbrow
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 6.208

4.  Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers.

Authors:  Yi Li; Wei Guo; Xiuqin Li; Jianguo Zhang; Moyi Sun; Zhangui Tang; Wei Ran; Kai Yang; Guilin Huang; Longjiang Li
Journal:  Int J Oral Sci       Date:  2021-11-16       Impact factor: 6.344

5.  Overexpression of p53 due to excess protein O-GlcNAcylation is associated with coronary microvascular disease in type 2 diabetes.

Authors:  Rui Si; Qian Zhang; Atsumi Tsuji-Hosokawa; Makiko Watanabe; Conor Willson; Ning Lai; Jian Wang; Anzhi Dai; Brian T Scott; Wolfgang H Dillmann; Jason X-J Yuan; Ayako Makino
Journal:  Cardiovasc Res       Date:  2020-05-01       Impact factor: 10.787

Review 6.  The Rich World of p53 DNA Binding Targets: The Role of DNA Structure.

Authors:  Václav Brázda; Miroslav Fojta
Journal:  Int J Mol Sci       Date:  2019-11-09       Impact factor: 5.923

7.  p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture.

Authors:  Aline Rangel-Pozzo; Samuel Booth; Pak Lok Ivan Yu; Madhurendra Singh; Galina Selivanova; Sabine Mai
Journal:  J Clin Med       Date:  2020-02-22       Impact factor: 4.241

8.  Amarogentin Inhibits Liver Cancer Cell Angiogenesis after Insufficient Radiofrequency Ablation via Affecting Stemness and the p53-Dependent VEGFA/Dll4/Notch1 Pathway.

Authors:  Yongchuan Zhang; Yinglin Zhang; Jin Wang; Haitao Gu
Journal:  Biomed Res Int       Date:  2020-10-20       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.